Literature DB >> 15081612

Fc gamma receptors.

Joël F G Cohen-Solal1, Lydie Cassard, Wolf-Herman Fridman, Catherine Sautès-Fridman.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15081612     DOI： 10.1016/j.imlet.2004.01.012

Source DB:  PubMed          Journal:  Immunol Lett        ISSN： 0165-2478            Impact factor:   3.685


× No keyword cloud information.
  27 in total

1.  Extravasations and emigration of neutrophils to the inflammatory site depend on the interaction of immune-complex with Fcgamma receptors and can be effectively blocked by decoy Fcgamma receptors.

Authors:  Rangaiah Shashidharamurthy; Randolph A Hennigar; Sebastien Fuchs; Purani Palaniswami; Melanie Sherman; Periasamy Selvaraj
Journal:  Blood       Date:  2007-10-25       Impact factor: 22.113

2.  Engineered antibody Fc variants with enhanced effector function.

Authors:  Greg A Lazar; Wei Dang; Sher Karki; Omid Vafa; Judy S Peng; Linus Hyun; Cheryl Chan; Helen S Chung; Araz Eivazi; Sean C Yoder; Jost Vielmetter; David F Carmichael; Robert J Hayes; Bassil I Dahiyat
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

Review 3.  Platelet-bacterial interactions.

Authors:  Steven W Kerrigan; Dermot Cox
Journal:  Cell Mol Life Sci       Date:  2009-11-29       Impact factor: 9.261

4.  Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.

Authors:  Roger S Riley; David Williams; Micaela Ross; Shawn Zhao; Alden Chesney; Bradly D Clark; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

5.  Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region.

Authors:  Robert Mabry; Mridula Rani; Robert Geiger; Gene B Hubbard; Ricardo Carrion; Kathleen Brasky; Jean L Patterson; George Georgiou; B L Iverson
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

6.  Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life.

Authors:  Ranajoy Majumdar; Reza Esfandiary; Steven M Bishop; Hardeep S Samra; C Russell Middaugh; David B Volkin; David D Weis
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 7.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

8.  The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals.

Authors:  Maxime Veillette; Mathieu Coutu; Jonathan Richard; Laurie-Anne Batraville; Olina Dagher; Nicole Bernard; Cécile Tremblay; Daniel E Kaufmann; Michel Roger; Andrés Finzi
Journal:  J Virol       Date:  2014-10-22       Impact factor: 5.103

9.  Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells.

Authors:  Sang Taek Jung; Sai T Reddy; Tae Hyun Kang; M Jack Borrok; Inger Sandlie; Philip W Tucker; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-18       Impact factor: 11.205

10.  Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity.

Authors:  Diana Stauch; Annelie Dernier; Elizabeth Sarmiento Marchese; Kristina Kunert; Hans-Dieter Volk; Johann Pratschke; Katja Kotsch
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.